New therapeutic options for persistent low-level viremia in patients with chronic hepatitis B virus infection: Increase of entecavir dosage

Table 1 Relative potencies of various nucleos(t)ide analogs for inhibiting hepatitis B virus

Drug	EC50 (nM), mean ± SD	Difference (fold) from entecavir EC50	Ref.
Entecavir	5.3 ± 2.5	1	Yurdaydin et al[31], 2008
TAF	86.6	16	Gibson et al[32], 2016
Lamivudine	1491 ± 1033	281	Yurdaydin et al[31], 2008
CMX-157	1600	420	Pei et al[33], 2017
Tenofovir	2482 ± 1938	468	Yurdaydin et al[31], 2008
Adefovir	2636 ± 1549	497	Yurdaydin et al[31], 2008
Telbivudine	8950 ± 4803	1689	Yurdaydin et al[31], 2008

EC₅₀: Effective concentration of nucleos(t)ide analogs that results in 50% inhibition of HBV DNA production; TAF: Tenofovir alafenamide; CMX-157: Tenofovir conjugated with a lipid moiety.